beta

CTIC

CTI BioPharma Corp.

Ctic

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Market Cap: 64.7 Million

Primary Exchange: NASDAQ

Website: http://www.ctibiopharma.com

Shares Outstanding: 58 Million

Float: 53.4 Million

Dividend: (%)

Beta: 1.93950959197962

Sector: Health Technology

Industry: Pharmaceuticals: Other

Short Interest (Jan 12, 2018): 434 Thousand

Ethical Flags

Animal testing

Longest drawdown: 1507 trading days

From: 2014-01-21 To: 2019-11-12

Lowest Point:

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20

via: PR Newswire at 2019-06-13 03:00:00:000

SEATTLE , June 13, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City . Presentation details: About… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2017-01-03 10.0 1.0 10.0
Data provided by IEX Cloud